수술용 접착제 시장 : 제품 유형, 제제, 용도, 최종사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Surgical Glue Market is projected to grow by USD 3.69 billion at a CAGR of 6.05% by 2032.

Surgical Glue Market Introduction

Surgical glue, also known as tissue adhesive, surgical sealant, or surgical adhesive, is increasingly used to support wound closure, hemostasis, tissue sealing, and leakage prevention across cardiovascular, general, orthopedic, neurosurgical, gynecological, trauma, plastic, and minimally invasive procedures. The category includes cyanoacrylate adhesives, fibrin sealants, polyethylene glycol-based hydrogels, albumin-glutaraldehyde systems, gelatin-thrombin matrices, collagen-based products, and other bioadhesive formulations designed to reduce reliance on sutures, staples, and mechanical fixation where clinically appropriate.

Demand is supported by verified healthcare trends, including rising surgical procedure volumes, aging populations, higher prevalence of chronic diseases requiring operative intervention, and the shift toward shorter hospital stays and faster recovery pathways. Surgical glue is valued because it can improve procedural efficiency, reduce needle-stick exposure, limit tissue trauma, and support closure in anatomically challenging or fragile tissue environments. Adoption, however, remains shaped by product-specific clinical evidence, surgeon preference, reimbursement pathways, sterility assurance, storage requirements, applicator usability, and regulatory classification, particularly where adhesives contact blood, dura, lung, gastrointestinal tissue, or vascular structures.

Transformative Shifts in Surgical Adhesives

The surgical glue landscape is shifting from basic wound closure toward clinically specialized adhesive platforms designed for targeted tissue types, performance profiles, and surgical workflows. Hospitals are increasingly evaluating adhesives not only on acquisition cost, but also on total procedural value, including operating room time, post-operative complication risk, length of stay, readmission avoidance, and compatibility with laparoscopic, robotic, and endoscopic delivery systems.

Regulatory scrutiny is also transforming competition. In the United States, surgical adhesives may be regulated as medical devices, biologics, or combination products depending on composition and intended use, while the European Union Medical Device Regulation has increased clinical evidence, technical documentation, and post-market surveillance expectations. These requirements are encouraging manufacturers to invest in robust clinical data, biocompatibility testing, validated sterilization, risk management, usability engineering, and clearer product differentiation.

Innovation is moving toward bioresorbable, flexible, low-toxicity, fast-setting, and wet-field adhesive technologies. Demand is strongest where adhesives solve persistent surgical challenges, such as air leaks after lung surgery, cerebrospinal fluid leaks, vascular bleeding, skin closure, and sealing of friable tissues. As procurement teams pursue standardization, suppliers with broad portfolios, application training, reliable supply chains, and documented outcomes are gaining strategic relevance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the surgical glue value chain through materials discovery, manufacturing control, clinical decision support, quality assurance, and demand planning. In research and development, AI-enabled modeling can screen polymer structures, degradation profiles, viscosity ranges, curing behavior, mechanical strength, and tissue interaction characteristics before expensive laboratory validation, helping teams narrow formulation candidates faster while maintaining requirements for biocompatibility, toxicology, and sterilization stability.

In manufacturing and quality assurance, machine vision, predictive maintenance, and AI-supported statistical process controls can help identify batch variability, packaging defects, fill-volume inconsistencies, applicator issues, and sterility-risk signals earlier. This is relevant for surgical glue because adhesive performance is highly dependent on formulation consistency, delivery mechanism, storage conditions, temperature sensitivity, and shelf-life integrity.

In clinical and commercial settings, AI can support evidence generation by analyzing real-world data, surgical outcomes, adverse event patterns, and complication signals across procedure types. While AI does not replace surgeon judgment, clinical trials, or regulatory evidence, it can strengthen post-market surveillance, optimize inventory by procedure mix, improve training targeting, and help manufacturers align product education with high-need specialties.

Regional Dynamics Across Surgical Glue Demand

Asia-Pacific is a high-opportunity region for surgical glue due to expanding surgical capacity, medical tourism, rising healthcare expenditure, and growing adoption of minimally invasive procedures in China, India, Japan, South Korea, Australia, and ASEAN economies. Local price sensitivity remains important, but premium adoption is increasing in tertiary hospitals where surgeons prioritize hemostasis, leakage control, faster closure, and reliable performance in complex procedures.

North America remains one of the most mature regions, supported by advanced surgical infrastructure, high procedure volumes, strong reimbursement systems for many operative interventions, and rapid uptake of evidence-backed medical devices. The United States is particularly influential in clinical validation, regulatory benchmarking, and product commercialization, while Canada emphasizes health technology assessment, cost-effectiveness, safety, and procurement discipline across publicly funded hospital systems.

Europe is shaped by established hospital systems, specialized surgical centers, and stricter evidence requirements under the European Union Medical Device Regulation. Germany, France, Italy, Spain, and the United Kingdom continue to create demand for advanced sealants in cardiovascular, thoracic, neurosurgical, gastrointestinal, and general surgery applications. Latin America, led by Brazil and Mexico, is expanding gradually as private hospital networks adopt advanced wound closure, hemostatic, and tissue sealing technologies. The Middle East, especially GCC markets, is investing in specialty care, trauma centers, and high-acuity hospitals, while Africa presents longer-term demand tied to surgical access expansion, emergency care, trauma management, and public-private healthcare investment.

Group-Level Insights Shaping Adoption

Within ASEAN, surgical glue adoption is supported by rising hospital investment, medical tourism, and growth in elective and specialty surgeries across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Adoption patterns vary widely, with premium tissue adhesives and surgical sealants concentrated in tertiary centers, while cost-effective formulations are gaining attention for broader surgical use in public and private hospitals.

The GCC is becoming a strategic market because of government-backed healthcare modernization, high-income patient populations, and investments in cardiovascular, trauma, oncology, transplant, and advanced surgical services. Hospitals in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman often prioritize internationally approved technologies with strong clinical evidence, reliable supplier support, and structured clinician training.

The European Union is highly regulated and evidence-driven, making CE marking under the EU MDR, clinical evaluation, technical documentation, and post-market performance central to access. BRICS economies combine large procedure volumes with diverse reimbursement and procurement environments, creating opportunities for tiered pricing, localized distribution, and domestic manufacturing partnerships. G7 countries remain innovation leaders due to strong academic medicine, established surgical societies, advanced regulatory systems, and high clinical evidence expectations, while NATO member countries add demand through trauma readiness, defense medical capabilities, emergency surgical preparedness, and resilient medical supply planning.

Country-Level Surgical Glue Insights

The United States leads surgical glue commercialization through high surgical volumes, strong specialist adoption, sophisticated hospital purchasing, and a regulatory framework that rewards clinically validated technologies. Canada offers steady demand through hospital systems that emphasize safety, procurement discipline, cost-effectiveness, and evidence-based product selection. Mexico and Brazil are key Latin American markets where private hospitals, urban specialty centers, and expanding surgical capacity support early adoption of advanced wound closure and hemostatic products.

In Europe, the United Kingdom supports demand through advanced surgical practice and health economic scrutiny, while Germany's high procedural intensity, specialized hospitals, and medical device ecosystem make it a core market for surgical adhesives and sealants. France, Italy, and Spain show sustained use in hospital-based surgical care, though procurement pressure, reimbursement rules, and regional purchasing structures shape adoption. Russia remains a sizable but complex market influenced by import dynamics, localization priorities, regulatory requirements, and healthcare investment variability.

China is expanding rapidly due to healthcare infrastructure growth, domestic device innovation, and increasing access to advanced surgical procedures. India presents significant long-term opportunity as procedure volumes rise and private hospitals adopt advanced closure technologies, although affordability and reimbursement remain decisive. Japan values premium, evidence-backed products and precision surgical practice, while Australia and South Korea show strong demand in specialized hospitals with high standards for safety, training, infection control, and clinical performance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize procedure-specific evidence that demonstrates measurable value, including reduced closure time, leakage prevention, hemostatic performance, lower complication rates, fewer reinterventions, and compatibility with minimally invasive techniques. Clinical claims must be aligned with approved indications and supported by well-designed studies, registries, usability assessments, or real-world evidence.

Manufacturers should segment portfolios by tissue type, specialty, risk profile, and healthcare setting rather than relying on a single universal adhesive message. Training programs for surgeons, nurses, and operating room staff are essential because application technique, surface preparation, field moisture, temperature, and curing conditions directly affect outcomes.

Commercial teams should strengthen regional market access strategies, including EU MDR readiness, FDA pathway planning, local distributor qualification, reimbursement mapping, tender preparation, and procurement-focused value dossiers. Strategic partnerships with hospitals, academic centers, simulation programs, and robotic or endoscopic device ecosystems can accelerate adoption in high-growth surgical segments.

Research Methodology

The research methodology for this executive summary integrates secondary research, regulatory review, clinical evidence assessment, and market triangulation. Sources considered include public regulatory frameworks, hospital procurement trends, peer-reviewed surgical literature, clinical practice patterns, product category disclosures, adverse event monitoring principles, and macro healthcare indicators such as surgical capacity, demographic aging, chronic disease burden, and minimally invasive surgery adoption.

Insights are validated by comparing product category behavior across regions, procedure types, material classes, and regulatory classifications. The analysis emphasizes verified drivers and constraints rather than unsupported market-size, market-share, or forecasting claims. Particular attention is given to clinical utility, material science differentiation, safety expectations, reimbursement sensitivity, usability, sterilization, shelf-life requirements, and post-market evidence obligations that influence surgical glue adoption.

Conclusion

The surgical glue market is evolving from a wound closure adjunct into a strategic surgical technology category spanning hemostasis, sealing, tissue repair, and minimally invasive procedure support. Growth is supported by rising procedure volumes, minimally invasive surgery, aging demographics, chronic disease prevalence, and hospital demand for efficient, evidence-backed solutions.

Competitive advantage will depend on clinical proof, regulatory execution, material innovation, application training, supply reliability, and the ability to demonstrate total procedural value. Organizations that align advanced adhesive science with surgeon needs, payer expectations, procurement requirements, and regional market access standards will be best positioned for durable relevance in surgical care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Surgical Glue Market, by Product Type

• 7.1. Biological Adhesive
  • 7.1.1. Albumin
  • 7.1.2. Fibrin Sealant
• 7.2. Synthetic Adhesive
  • 7.2.1. Cyanoacrylate
  • 7.2.2. Polyethylene Glycol Hydrogel

8. Surgical Glue Market, by Formulation

• 8.1. Liquid
  • 8.1.1. Dual Component
  • 8.1.2. Single Component
• 8.2. Patch
  • 8.2.1. Natural Patch
  • 8.2.2. Synthetic Patch
• 8.3. Spray
  • 8.3.1. Aerosol Spray
  • 8.3.2. Jet Spray

9. Surgical Glue Market, by Application

• 9.1. Cardiovascular Surgery
  • 9.1.1. Heart Valve Replacement
  • 9.1.2. Vascular Repair
• 9.2. Dental
• 9.3. General Surgery
  • 9.3.1. Abdominal Procedures
  • 9.3.2. Thoracic Procedures
• 9.4. Ophthalmic Surgery
• 9.5. Orthopedic Surgery
  • 9.5.1. Bone Fixation
  • 9.5.2. Joint Repair

10. Surgical Glue Market, by End User

• 10.1. Ambulatory Surgical Center
• 10.2. Clinic
  • 10.2.1. Outpatient Clinic
  • 10.2.2. Specialty Clinic
• 10.3. Hospital
  • 10.3.1. Private Hospital
  • 10.3.2. Public Hospital

11. Surgical Glue Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Surgical Glue Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Surgical Glue Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Surgical Glue Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 3M Company
• 16.2. Adhesys Medical GmbH
• 16.3. Adhezion Biomedical LLC
• 16.4. Advanced Medical Solutions Group plc
• 16.5. Artivion, Inc.
• 16.6. B. Braun Melsungen AG
• 16.7. Baxter International Inc.
• 16.8. Becton, Dickinson and Company
• 16.9. Cardinal Health, Inc.
• 16.10. Chemence Medical, Inc.
• 16.11. Cohera Medical, LLC
• 16.12. Connexicon Medical Limited
• 16.13. Covalon Technologies Ltd.
• 16.14. CSL Limited
• 16.15. GEM S.r.l.
• 16.16. Hollister Incorporated
• 16.17. Integra LifeSciences Corporation
• 16.18. Johnson & Johnson Services, Inc.
• 16.19. Medtronic plc
• 16.20. Meyer-Haake GmbH Medical Innovations
• 16.21. Ocular Therapeutix, Inc.
• 16.22. Polyganics BV
• 16.23. Smith & Nephew plc
• 16.24. Solventum Corporation
• 16.25. Stryker Corporation
• 16.26. Terumo Corporation
• 16.27. Tissium SA
• 16.28. Vivostat A/S